Annual CFO
-$237.73 M
-$17.21 M-7.81%
31 December 2023
Summary:
Allogene Therapeutics annual cash flow from operations is currently -$237.73 million, with the most recent change of -$17.21 million (-7.81%) on 31 December 2023. During the last 3 years, it has fallen by -$122.64 million (-106.56%). ALLO annual CFO is now -432.40% below its all-time high of -$44.65 million, reached on 31 December 2018.ALLO Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$44.12 M
+$19.47 M+30.62%
30 September 2024
Summary:
Allogene Therapeutics quarterly cash flow from operations is currently -$44.12 million, with the most recent change of +$19.47 million (+30.62%) on 30 September 2024. Over the past year, it has increased by +$11.41 million (+20.56%). ALLO quarterly CFO is now -882400.00% below its all-time high of $5000.00, reached on 31 March 2018.ALLO Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$217.31 M
+$11.41 M+4.99%
30 September 2024
Summary:
Allogene Therapeutics TTM cash flow from operations is currently -$217.31 million, with the most recent change of +$11.41 million (+4.99%) on 30 September 2024. Over the past year, it has increased by +$28.81 million (+11.71%). ALLO TTM CFO is now -4346280.00% below its all-time high of $5000.00, reached on 31 March 2018.ALLO TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ALLO Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -7.8% | +20.6% | +11.7% |
| 3 y3 years | -106.6% | +9.7% | -45.5% |
| 5 y5 years | -432.4% | -38.1% | -100.2% |
ALLO Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -106.6% | at low | -3.7% | +35.4% | -45.5% | +11.7% |
| 5 y | 5 years | -432.4% | at low | -342.3% | +35.4% | -100.2% | +11.7% |
| alltime | all time | -432.4% | at low | <-9999.0% | +35.4% | <-9999.0% | +11.7% |
Allogene Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$44.12 M(-30.6%) | -$217.31 M(-5.0%) |
| June 2024 | - | -$63.59 M(+13.8%) | -$228.72 M(+0.8%) |
| Mar 2024 | - | -$55.90 M(+4.1%) | -$226.99 M(-4.5%) |
| Dec 2023 | -$237.73 M(+7.8%) | -$53.71 M(-3.3%) | -$237.73 M(-3.4%) |
| Sept 2023 | - | -$55.53 M(-10.2%) | -$246.12 M(+3.3%) |
| June 2023 | - | -$61.86 M(-7.2%) | -$238.25 M(+8.8%) |
| Mar 2023 | - | -$66.64 M(+7.3%) | -$218.92 M(-0.7%) |
| Dec 2022 | -$220.52 M(+19.3%) | -$62.10 M(+30.3%) | -$220.52 M(+8.2%) |
| Sept 2022 | - | -$47.66 M(+12.0%) | -$203.86 M(-0.6%) |
| June 2022 | - | -$42.53 M(-37.7%) | -$205.08 M(+0.7%) |
| Mar 2022 | - | -$68.24 M(+50.2%) | -$203.72 M(+10.2%) |
| Dec 2021 | -$184.81 M | -$45.44 M(-7.0%) | -$184.81 M(+23.7%) |
| Sept 2021 | - | -$48.88 M(+18.7%) | -$149.35 M(+8.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2021 | - | -$41.17 M(-16.5%) | -$138.06 M(+11.7%) |
| Mar 2021 | - | -$49.33 M(+394.5%) | -$123.61 M(+7.4%) |
| Dec 2020 | -$115.09 M(-16.2%) | -$9.97 M(-73.5%) | -$115.09 M(-25.9%) |
| Sept 2020 | - | -$37.59 M(+40.7%) | -$155.38 M(+3.8%) |
| June 2020 | - | -$26.72 M(-34.5%) | -$149.73 M(+1.2%) |
| Mar 2020 | - | -$40.81 M(-18.8%) | -$147.90 M(+7.7%) |
| Dec 2019 | -$137.35 M(+207.6%) | -$50.27 M(+57.4%) | -$137.35 M(+26.5%) |
| Sept 2019 | - | -$31.93 M(+28.3%) | -$108.56 M(+15.8%) |
| June 2019 | - | -$24.89 M(-17.7%) | -$93.76 M(+25.2%) |
| Mar 2019 | - | -$30.26 M(+40.9%) | -$74.91 M(+67.8%) |
| Dec 2018 | -$44.65 M | -$21.48 M(+25.4%) | -$44.65 M(+92.7%) |
| Sept 2018 | - | -$17.13 M(+183.3%) | -$23.17 M(+283.5%) |
| June 2018 | - | -$6.05 M(<-9900.0%) | -$6.04 M(<-9900.0%) |
| Mar 2018 | - | $5000.00 | $5000.00 |
FAQ
- What is Allogene Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Allogene Therapeutics?
- What is Allogene Therapeutics annual CFO year-on-year change?
- What is Allogene Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Allogene Therapeutics?
- What is Allogene Therapeutics quarterly CFO year-on-year change?
- What is Allogene Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Allogene Therapeutics?
- What is Allogene Therapeutics TTM CFO year-on-year change?
What is Allogene Therapeutics annual cash flow from operations?
The current annual CFO of ALLO is -$237.73 M
What is the all time high annual CFO for Allogene Therapeutics?
Allogene Therapeutics all-time high annual cash flow from operations is -$44.65 M
What is Allogene Therapeutics annual CFO year-on-year change?
Over the past year, ALLO annual cash flow from operations has changed by -$17.21 M (-7.81%)
What is Allogene Therapeutics quarterly cash flow from operations?
The current quarterly CFO of ALLO is -$44.12 M
What is the all time high quarterly CFO for Allogene Therapeutics?
Allogene Therapeutics all-time high quarterly cash flow from operations is $5000.00
What is Allogene Therapeutics quarterly CFO year-on-year change?
Over the past year, ALLO quarterly cash flow from operations has changed by +$11.41 M (+20.56%)
What is Allogene Therapeutics TTM cash flow from operations?
The current TTM CFO of ALLO is -$217.31 M
What is the all time high TTM CFO for Allogene Therapeutics?
Allogene Therapeutics all-time high TTM cash flow from operations is $5000.00
What is Allogene Therapeutics TTM CFO year-on-year change?
Over the past year, ALLO TTM cash flow from operations has changed by +$28.81 M (+11.71%)